Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center

No Dose Adjustment for Isavuconazole Based on Age or Sex

(2019) Amit V. Desai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy

(2019) E Furfaro et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Isavuconazole Treatment of Cerebral and Pulmonary Aspergillosis in a Pediatric Patient With Acute Lymphoblastic Leukemia

(2019) Francesco De Leonardis et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis

(2019) Laura L. Kovanda et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials

(2018) David Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial

(2018) Bart Jan Kullberg et al.   CLINICAL INFECTIOUS DISEASES

Variability and exposure–response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases

(2018) Thomas Kaindl et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations

(2017) Katharine E. Stott et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)

(2016) Laura L. Kovanda et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi

(2016) Amit Desai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

(2016) Johan A Maertens et al.   LANCET

A Phase 2, Randomized, Double-Blind, Multicenter Trial To Evaluate the Safety and Efficacy of Three Dosing Regimens of Isavuconazole Compared with Fluconazole in Patients with Uncomplicated Esophageal Candidiasis

(2015) J. Viljoen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent

(2015) Marisa H. Miceli et al.   CLINICAL INFECTIOUS DISEASES

Isavuconazole Treatment of a Patient with Disseminated Mucormycosis

(2014) D. Peixoto et al.   JOURNAL OF CLINICAL MICROBIOLOGY